The process of approving drugs, with the huge bets placed on their outcome, has always been a fertile ground for potential insider trading. A hint of success in a clinical trial can send shares of a biotechnology company surging.
The best-known example is that of Samuel D. Waksal, the former chief executive of ImClone Systems, who pleaded guilty to charges that he tipped off family members to sell shares shortly before an unfavorable regulatory ruling.
